Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910)
Phase 2
- Conditions
- nresectable stage III/IV and relapsed after resection squamous cell lung cancer
- Registration Number
- JPRN-UMIN000003330
- Lead Sponsor
- Thoracic Oncology Research Group (TORG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Massive pleural effusion 2)Massive pericardial effusion 3)double cancer 4)severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, ued uncontrolled diabetis mellitus, uncontrolled infection, uncontrolled mental disease, SVC syndrome 5)irinotecan contraindication; watery diarrhea, ileus, digestive organs bleeding, jaundice, bone marrow suppression 6)nedaplatin contraindication; renal failure 7)lung fibrosis 8)pregnancy 9)other inappropriate cases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method